Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. The 1990s were a period of significant change for both the Czech nation and its healthcare sector. The government has decentralised the health sector through methods of rationalisation and large scale privatisation, and created a health system with a diverse mixture of establishments. The introduction of a health insurance scheme has also played an important part in the development of Czech healthcare.

The Czech pharmaceutical sector remains one of the better regional prospects for overseas suppliers, being relatively wealthy and largely reliant on imported medicines. The international pharmaceutical industry has continued to challenge the government over its dubious pricing and reimbursement criteria and IP protection remains an area that needs strengthening. However, much of the country's regulatory structure has been aligned with EU Directives and other amendments are expected in the near future. The Czech Republic attained full EU membership in May 2004.